brant schofield

P&L responsibility for the Specialty Products Division of Mayne Pharma including Dermatology, Infectious Disease and Women's Health Businesses.

Worked with startup incubators and university tech transfer departments to commericalize new technologies primarily in the medical field. Built and currently maintain relationships with venture capital and private equity.

Galderma North America, the leader in Dermatology, is a +$1B business operating in the RX, Aesthetic and OTC Skin Health markets. Responsible for establishing Galderma's presence in the generic dermatology space and maximizing the value of the branded portfolio post loss of exclusivity. Created and developed Owen Laboratories, Inc. as the generic division of Galderma currently serving as President. Owen business currently represents +$150M in revenue in the retail, specialty pharmacy and authorized generic businesses.

Responsible for the US branded pharmaceutical business for Taro. Concentrating on dermatology and pediatrics, responsible for $100M in business and a 75 person organization. Manage sales, marketing, managed care, medical directly. Liason with Sun and Taro R&D and Business Development for organic pipeline and external acquisition and licensing.

* Responsible for $150M in sales and 400 people across 7 wholly owned affiliates and 15 countries. Grew sales by 25% and profitability by 30% in 2 years. * Reorganized and relocated the area management team from Paris, France to Texas. * Refocused Latin America on OTC overall business resulting in a 500% growth across the region. * Acquired Dysport (2nd Botox) from Ipsen in Brazil and Argentina to establish the aesthetic business. * Gained approval for Metvixia and Epiduo and launched across the region. * Switched Loceryl from prescription to OTC in Venezuela, Brazil and Mexico resulting in a 300% growth in sales.

* Led finance and administration for Galderma USA reporting to the President, Galderma USA with a dotted line to the CFO, Galderma Worldwide. * Managed accounting, financial reporting, internal controls, budgeting/planning, decision support and business development. Also responsible for supply chain and distribution. * International tax and transfer pricing specialist.

Relocated to France corporate headquarters to create and implement corporate financial functions that did not exist in, what was at the time, a small corporate structure. Reported directly to the Worldwide CFO. Introduced financial valuation and evaluation processes and techniques for purposes of evaluating business development opportunities and internal R&D projects. Expanded the project to include practical execution elements including customer transition, logistics and manufacturing. Worked on the acquisitions of Loceryl, Basotherm Germany, Metvix, Silkis, Solage. Worked directly with the Worldwide CFO to reorganize the worldwide Galderma group from a tax perspective. The transfer pricing strategy that was implemented has saved $600M USD over the last 9 years.

Led finance and administration for Galderma EURMEAA reporting to the Area Vice President, EURMEAA with a dotted line to the CFO, Galderma Worldwide. Managed 10 Country Finance Directors, in a matrix organization, representing virtually all of the viable countries in Europe, Middle East, Africa and Australia. Led a major reorganization of the Area with the Area VP resulting in 80% turnover of management teams in the countries. This subsequently resulted in sales growth of +10% and a 10% improvement in profitability (20% to 30%). As Interim General Manager of Galderma UK, led the reorganization of product portfolio and sales organization resulting in significant growth and financial viability. Today Galderma UK is 3rd in sales in EURMEAA and 5th in the world.

In June 2014 Nestle acquired 100% of Galderma SA and created a new parent company, Nestle Skin Health. Moved from Galderma to Nestle Skin Health as Global Vice President of New Business in April 2015. Responsible for identifying new businesses and business models to incorporate into the Nestle Skin Health ecosystem. Once identified and acquired, responsible for integration and operationalizing the new businesses. I maintain my role as President of Owen Laboratories and the branded, generic business of Galderma in a dual role.

Full P&L responsibility for both the branded and generic dermatology business at Sandoz. Responsible for leading the day to day operations for the dermatology business including sales, marketing, manufacturing and all other aspects required to operate a pharmaceutical company. Also responsible for establishing the product portfolio strategy and implementing that strategy through internal development and external BD&L opportunities.